Tango Therapeutics Launches Phase 1/2 Trial for Cancer Patients
Tango Therapeutics, Inc. (NASDAQ: TNGX), a pioneering biotechnology company focused on advancing precision medicine, has recently announced the dosing of its first patient in an innovative Phase 1/2 clinical trial. This trial investigates the effects of TNG462 in conjunction with two specific medications, daraxonrasib and zoldonrasib, aimed at treating patients suffering from metastatic pancreatic or lung cancers that lack the MTAP gene and present RAS mutations.
Understanding the Clinical Significance
Research indicates that nearly all patients with MTAP-deleted pancreatic cancer—and approximately 30% of those with lung cancer—have an accompanying mutation in the RAS gene, making this combination therapy highly critical. Adam Crystal, M.D., Ph.D., who serves as the President of Research and Development at Tango Therapeutics, shared insights on the promising preclinical data showcasing the strong synergies between TNG462 and the two Revolution Medicines' inhibitors. These findings suggest that such combinations could potentially revolutionize cancer treatment.
The Phase 1/2 Trial Details
The trial, identified by the clinical trial number NCT06922591, aims to comprehensively evaluate the safety and effectiveness of TNG462 alongside daraxonrasib and zoldonrasib. It will measure important factors like pharmacokinetics—the study of how drugs move through the body—and the drugs' ability to combat tumors, specifically in pancreatic and lung cancer patients who are both MTAP-deleted and harboring RAS mutations.
Potential Breakthrough with TNG462
TNG462 has emerged as a promising MTA-cooperative PRMT5 inhibitor. Currently, it is undergoing evaluation as a standalone treatment in a separate Phase 1/2 trial. Initial results from this monotherapy study are expected in the latter half of 2025. The insights gained from this data may be pivotal in setting the foundation for a pivot towards a registrational trial for pancreatic cancer in the coming years, alongside refining development strategies for lung cancer treatment.
About Tango Therapeutics
Tango Therapeutics is committed to redefining cancer treatment by developing novel drug targets and innovative therapies. The company's cutting-edge approach harnesses the concept of synthetic lethality, targeting specific vulnerabilities in cancer cells to create effective treatment regimens. By focusing on regular patient input and genetic understanding, Tango aims to bring forward the next generation of cancer therapies.
Connecting with Investors and the Media
This innovative work led by Tango Therapeutics reflects the company’s dedication to solving unmet medical needs in the oncology field. Investors and media representatives seeking further information are encouraged to contact:
Elizabeth Hickin
IR@tangotx.com
media@tangotx.com
Frequently Asked Questions
What is TNG462 used for?
TNG462 is a novel drug candidate designed to treat patients with MTAP-deleted and RAS mutant pancreatic or lung cancers.
How does the clinical trial work?
The Phase 1/2 trial will assess the safety, pharmacokinetics, and pharmacodynamics of TNG462 when combined with daraxonrasib and zoldonrasib in cancer patients.
What are the expected benefits of this combination therapy?
The combination aims to enhance therapeutic effectiveness and improve outcomes for patients with certain mutations in pancreatic or lung cancer.
When will results from the trial be available?
Initial data from the ongoing monotherapy trial of TNG462 is anticipated in the latter half of 2025, which may influence future development strategies.
How does Tango Therapeutics approach drug development?
Tango employs a patient-centered approach, focusing on synthetic lethality principles to identify and create effective cancer therapies.
